FilingReader Intelligence
Chongqing Zhifei revenue plunges 73% despite vaccine progress
August 18, 2025 at 05:39 PM UTC•By FilingReader AI
Chongqing Zhifei Biological Products reported revenue fell 73% to 4.92 billion yuan in its semi-annual results, citing declining vaccination willingness and market demand.
The company received clinical trial approval for a combined vaccine targeting adolescents and adults, covering pertussis, diphtheria and tetanus.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
2025 half-yearly reportAugust 18, 2025 at 08:00 AM UTC
Announcement regarding the acceptance of the clinical trial application for the company's adsorbed acellular diphtheria, tetanus, and acellular pertussis (component) combined vaccine (for adults and adolescents)August 18, 2025 at 08:00 AM UTC
Announcement of resolutions of the board of supervisorsAugust 18, 2025 at 08:00 AM UTC
Announcement of board resolutionAugust 18, 2025 at 08:00 AM UTC
Summary table of non-operating fund occupation and other related party fund transactions for the first half of 2025August 18, 2025 at 08:00 AM UTC
News Alerts
Get instant email alerts when Chongqing Zhifei Biological Products publishes news
Free account required • Unsubscribe anytime